Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type.
It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
The company was founded in 2002 and is based in Coral Gables, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | 0.35 Increased by +220.69% | 0.30 Increased by +16.67% |
| Aug 7, 24 | 0.33 Decreased by -37.74% | 0.26 Increased by +26.92% |
| May 8, 24 | 0.19 Decreased by -26.92% | 0.17 Increased by +11.76% |
| Feb 28, 24 | 0.31 Increased by +40.91% | 0.27 Increased by +14.81% |
| Nov 8, 23 | -0.29 Decreased by -245.00% | -0.28 Decreased by -3.57% |
| Aug 9, 23 | 0.53 Increased by +165.00% | 0.42 Increased by +26.19% |
| May 10, 23 | 0.26 Increased by +116.67% | 0.32 Decreased by -18.75% |
| Mar 15, 23 | 0.22 Increased by +144.44% | 0.21 Increased by +4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 128.69 M Increased by +25.33% | 43.88 M Increased by +242.65% | Increased by +34.10% Increased by +213.82% |
| Jun 30, 24 | 122.71 M Increased by +23.23% | 40.79 M Increased by +8.03% | Increased by +33.24% Decreased by -12.33% |
| Mar 31, 24 | 98.51 M Increased by +15.40% | 23.27 M Decreased by -21.28% | Increased by +23.63% Decreased by -31.79% |
| Dec 31, 23 | 110.57 M Increased by +81.98% | 34.84 M Increased by +36.80% | Increased by +31.51% Decreased by -24.83% |
| Sep 30, 23 | 102.69 M Increased by +79.39% | -30.76 M Decreased by -235.24% | Decreased by -29.96% Decreased by -175.39% |
| Jun 30, 23 | 99.58 M Increased by +87.49% | 37.76 M Increased by +74.67% | Increased by +37.92% Decreased by -6.84% |
| Mar 31, 23 | 85.37 M Increased by +98.12% | 29.57 M Increased by +123.31% | Increased by +34.64% Increased by +12.72% |
| Dec 31, 22 | 60.76 M Increased by +58.60% | 25.47 M Increased by +173.62% | Increased by +41.92% Increased by +72.52% |